Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

KNOX, T., SAHAKIAN, E., BANIK, D., HADLEY, M., PALMER, E., NOONEPALLE, S., KIM, J., POWERS, J., GRACIA-HERNANDEZ, M., OLIVEIRA, V., CHENG, F., CHEN, J., BAŘINKA, Cyril, PINILLA-IBARZ, J., LEE, N. H., KOZIKOWSKI, A., VILLAGRA, A. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 2019, 9(APR 16 2019), 6136. ISSN 2045-2322. E-ISSN 2045-2322. Available: doi: 10.1038/s41598-019-42237-3.